Search This Blog

Tuesday, March 17, 2026

Pulse Bio to prioritize Cardiac Catheter Ablation System, shifting capital from surgical, tissue programs

 

Pulse Biosciences realigns strategy to prioritize nPulse Cardiac Catheter Ablation System, reallocating capital from surgical and soft-tissue programs

  • Strategic realignment follows strong long-term AFib feasibility data for the nPulse Cardiac Catheter Ablation System.
  • Company reallocates capital away from surgical and soft-tissue programs to accelerate development and future commercialization efforts.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)